BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  Approvals

  FDA Approves Atopic Dermatitis Label Expansion for Arcutis’ Zoryve Cream

  The regulator Tuesday added atopic dermatitis to the label of Arcutis Biotherapeutics’ topical PDE4 inhibitor Zoryve for the treatment of patients six years of age and older.

  July 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  CAR-T

  Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia

  Interius BioTherapeutics has received approval from Australia’s Human Research Ethics Committee to begin the first-in-human trial of an investigational in vivo CAR-T therapy designed to treat B-cell malignancies.

  July 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Deals

  Spine BioPharma, Inc. Announces Agreement with Ensol BioSciences, Inc. to Expand Indications for SB-01 For Injection

  July 10, 2024

   · 

  2 min read
• Deals

  Nusano and PharmaLogic Announce Strategic Supply Agreement to Enable Current and Emerging Radiopharmaceuticals

  July 10, 2024

   · 

  3 min read
• 

  Opinion

  To Realize AI’s Benefits, Don’t Lose Sight of Fundamentals

  Artificial intelligence is making it faster to get drug candidates to the clinic, but to gain a competitive advantage, companies must have a strong foundation of data.
  

  July 10, 2024

   · 

  4 min read

   · 

  Thomas Swalla
• 

  Business

  VC Firm Flagship Raises $3.6B to Create, Support 25 ‘Breakthrough’ Companies

  Biotech venture capital firm Flagship Pioneering is looking to fund companies focused on artificial intelligence, human health and sustainability, bringing the total raised since 2021 to $6.4 billion.

  July 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors

  Amgen has quietly discontinued the development of its Phase I bispecific T-cell engager AMG 794, which the company had been studying for several malignant solid tumors.

  July 10, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & Acquisitions

  Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger
  
  

  After pulling its ALS drug Relyvrio from the market, Amylyx Pharmaceuticals is looking to target the GLP-1 space with the purchase of Eiger BioPharmaceuticals’ avexitide, which has been studied for the treatment of hyperinsulinemic hypoglycemia.

  July 10, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Cardiovascular Disease

  Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data
  
  

  Preliminary data from a late-stage trial of Alnylam’s RNAi therapy for ATTR amyloidosis with cardiomyopathy appear strong but details expected later this summer are critical.
  
  

  July 10, 2024

   · 

  3 min read

   · 

  Tyler Patchen
• Press Releases

  Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

  July 10, 2024

   · 

  1 min read